Latest News
Emergent cuts 300 jobs and shutters two facilities
Emergent cuts 300 jobs and shutters two facilities
As part of its restructuring plan, Emergent BioSolutions will cut around 300 jobs across all areas of its business and shut down its facilities in Bayview, Baltimore and Rockville, Maryland.
Deal-Making
Alvotech will produce its interchangeable biosimilar to Humira (adalimumab) under a private label for Quallent Pharmaceuticals.
Ingersoll, a provider of industrial solutions, will acquire ILC from investment firm New Mountain Capital to add technologies for life science applications to its arsenal.
Facilities & Capacity
As part of its restructuring plan, Emergent BioSolutions will cut around 300 jobs across all areas of its business and shut down its facilities in Bayview, Baltimore and Rockville, Maryland.
Asimov has launched a stable cell line development service, which it claims is 10 times more efficient in lentiviral production.
Global Markets
Thermo Fisher Scientific highlighted the BIOSECURE Act and the pending Catalent/Novo deal as potential drivers for its CDMO business during its Q1 earnings call.
Sartorius has closed its first quarter positively “in line” with expectations but highlights China as a continued market weakness.
Regulations
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
CDMO AGC Bio will supply lentiviral vectors for Orchard Therapeutics’ metachromatic leukodystrophy (MLD) gene therapy, approved in the US this week.
Therapeutic Class
Contract development and manufacturing organization (CDMO) Oxford Biomedica has launched its One OXB strategy in an effort to align its global footprint.
Bioprocess vendors have welcomed China’s Stimulus Package as a “positive development,” amid several headwinds driven by dried up funds.
Upstream & Downstream Processing
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a 330,000 L California facility to CDMO Lonza.
Nigel Titchener-Hooker, professor and dean of engineering at University College London, guided delegates at BioProcess International Europe in Vienna, Austria, on a tour through drug-development history.